Publication:
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Simple item page
dc.contributor.authorCassinello, J
dc.contributor.authorArranz, J Á
dc.contributor.authorPiulats, J M
dc.contributor.authorSánchez, A
dc.contributor.authorPérez-Valderrama, B
dc.contributor.authorMellado, B
dc.contributor.authorCliment, M Á
dc.contributor.authorOlmos, D
dc.contributor.authorCarles, J
dc.contributor.authorLázaro, M
dc.date.accessioned2024-01-23T20:13:18Z
dc.date.available2024-01-23T20:13:18Z
dc.date.issued2017-11-13
dc.description.abstractAndrogen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
dc.format.number1es_ES
dc.format.page57-68es_ES
dc.format.volume20es_ES
dc.identifier.doi10.1007/s12094-017-1783-2
dc.identifier.e-issn1699-3055es_ES
dc.identifier.journalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/11795
dc.identifier.pubmedID29134562es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17346
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAbiraterone
dc.subjectAndrogen deprivation treatment
dc.subjectCabazitaxel
dc.subjectCastration-resistant prostate cancer
dc.subjectDocetaxel
dc.subjectEnzalutamide
dc.subjectHormone-sensitive advanced prostate cancer
dc.subjectRadium 223
dc.subject.meshAntineoplastic Agents
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.titleSEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)
IDIBAPS - Instituto de Investigaciones Biomédicas August Pi i Sunyer (Cataluña)